Published in Cancer Weekly, September 4th, 2001
High levels of the angiogenic growth factor VEGF has been identified in the blood of patients with different types of cancer. Boston, Massachusetts, Dana-Farber Cancer Institute researchers, in collaboration with investigators at several major U.S. research centers, propose plasma levels of VEGF are a significant indicator for survival in HRPC patients based on their evaluation of several Cancer and Leukemia Group B 9480...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.